JPWO2023064366A5 - - Google Patents

Info

Publication number
JPWO2023064366A5
JPWO2023064366A5 JP2024522052A JP2024522052A JPWO2023064366A5 JP WO2023064366 A5 JPWO2023064366 A5 JP WO2023064366A5 JP 2024522052 A JP2024522052 A JP 2024522052A JP 2024522052 A JP2024522052 A JP 2024522052A JP WO2023064366 A5 JPWO2023064366 A5 JP WO2023064366A5
Authority
JP
Japan
Prior art keywords
triazin
pyrrolo
amine
imidazo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539620A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/046416 external-priority patent/WO2023064366A1/en
Publication of JP2024539620A publication Critical patent/JP2024539620A/ja
Publication of JPWO2023064366A5 publication Critical patent/JPWO2023064366A5/ja
Pending legal-status Critical Current

Links

JP2024522052A 2021-10-12 2022-10-12 Dyrk1a阻害剤としてのピロロ[2,1-f][1,2,4]トリアジン誘導体 Pending JP2024539620A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163254733P 2021-10-12 2021-10-12
US63/254,733 2021-10-12
US202263347757P 2022-06-01 2022-06-01
US63/347,757 2022-06-01
PCT/US2022/046416 WO2023064366A1 (en) 2021-10-12 2022-10-12 Pyrrolo[2,1-f][1,2,4]triazines derivatives as inhibitors of dyrk1a

Publications (2)

Publication Number Publication Date
JP2024539620A JP2024539620A (ja) 2024-10-29
JPWO2023064366A5 true JPWO2023064366A5 (enExample) 2025-10-21

Family

ID=84330173

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522052A Pending JP2024539620A (ja) 2021-10-12 2022-10-12 Dyrk1a阻害剤としてのピロロ[2,1-f][1,2,4]トリアジン誘導体

Country Status (11)

Country Link
US (2) US12134625B2 (enExample)
EP (1) EP4415816A1 (enExample)
JP (1) JP2024539620A (enExample)
KR (1) KR20240089275A (enExample)
AU (1) AU2022367222A1 (enExample)
CA (1) CA3234831A1 (enExample)
IL (1) IL312157A (enExample)
MX (1) MX2024004552A (enExample)
TW (1) TW202322800A (enExample)
UY (1) UY39979A (enExample)
WO (1) WO2023064366A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023147372A1 (en) * 2022-01-25 2023-08-03 Kinnate Biopharma Inc. Inhibitors of cdk4/6 kinase
KR20250133646A (ko) * 2022-11-03 2025-09-08 바이오스플라이스 테라퓨틱스, 인크. 4-아미노피롤로[2,1-f][1,2,4]트라이아진 및 이의 제조 및 용도
WO2024211797A1 (en) * 2023-04-07 2024-10-10 Biosplice Therapeutics, Inc. Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof
CN119019402A (zh) * 2023-05-24 2024-11-26 中国科学院上海有机化学研究所 作为lrrk2激酶抑制剂的多环化合物及其制备方法和用途
WO2025024707A1 (en) * 2023-07-26 2025-01-30 Kinnate Biopharma Inc. Inhibitors of cdk2/4/6 kinase
WO2025137469A1 (en) * 2023-12-22 2025-06-26 Biosplice Therapeutics, Inc. 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
WO2005095400A1 (en) 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
EP1861161A4 (en) 2005-01-24 2012-05-16 Neurosystec Corp APPARATUS AND METHOD FOR DISPENSING THERAPEUTIC AND / OR OTHER AGENTS IN THE INTERNAL EAR AND OTHER FABRICS
EP2320895A2 (en) 2008-07-03 2011-05-18 Exelixis, Inc. Cdk modulators
WO2011018894A1 (en) 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
BR112015014752B1 (pt) 2012-12-21 2022-07-05 Plexxikon, Inc Compostos e seus uso para modulação de cinase
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
JP2018526452A (ja) 2015-09-03 2018-09-13 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ Dyrk1aの小分子抑制剤およびその使用
FR3041640B1 (fr) 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
AU2018347296A1 (en) * 2017-10-10 2020-05-07 Syros Pharmaceuticals, Inc. Pyrrolotriazine compounds and methods of inhibiting TAM kinases
US20200039989A1 (en) * 2018-03-01 2020-02-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk/clk and uses thereof
WO2019169306A1 (en) 2018-03-01 2019-09-06 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for suppressing toxic endoplasmic reticulum stress
US20220062240A1 (en) 2018-06-26 2022-03-03 Biosplice Therapeutics, Inc. Methods of treating cancer using a clk inhibitor
WO2020081689A1 (en) 2018-10-16 2020-04-23 Dana-Farber Cancer Institute, Inc. Azaindole inhibitors of wild-type and mutant forms of lrrk2
WO2020150552A2 (en) 2019-01-17 2020-07-23 Samumed, Llc Methods of treating cartilage disorders through inhibition of clk and dyrk
WO2021257863A1 (en) * 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
EP4182320A1 (en) 2020-07-20 2023-05-24 Nido Biosciences, Inc. Indole compounds as androgen receptor modulators
US20230192686A1 (en) 2021-10-12 2023-06-22 Biosplice Therapeutics, Inc. 1h-pyrrolo[2,3-b]pyridines and preparation and uses thereof
CA3234937A1 (en) 2021-10-12 2023-04-20 Biosplice Therapeutics, Inc. 7h-pyrrolo[2,3-d]pyrimidines and preparation as dyrk1a inhibitors
EP4543886A1 (en) 2022-06-23 2025-04-30 BioSplice Therapeutics, Inc. 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof

Similar Documents

Publication Publication Date Title
TWI619714B (zh) 作為pi3k抑制劑之雜環基胺
TWI657090B (zh) 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途
JP6432624B2 (ja) 3環性ヘテロ環化合物及びjak阻害剤
CN106061973B (zh) 吡咯并[2,3-d]嘧啶基、吡咯并[2,3-b]吡嗪基和吡咯并[2,3-d]吡啶基丙烯酰胺
US10519177B2 (en) Heterocyclic compounds and uses thereof
RU2742938C2 (ru) 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
CN118715215A (zh) 作为突变kras蛋白抑制剂的喹唑啉化合物及其用途
CN118974055A (zh) 作为突变kras蛋白抑制剂的喹唑啉化合物及其用途
JP2020515603A (ja) Hpk1阻害剤としてのイソキノリン
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
US20180072722A1 (en) Heterocyclic compounds and uses thereof
RU2009140469A (ru) Производные пирролопиримидин-7-она и их применение в качестве фармацевтических средств
TW201619159A (zh) 吡咯并[2,3-d]嘧啶衍生物
EP2548877A1 (en) 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
JP2017511365A5 (enExample)
KR20120093867A (ko) 비시클릭 헤테로아릴의 에테르 유도체
JP2020526549A5 (enExample)
JP2017522340A (ja) 6,7−ジヒドロピラゾロ[1,5−a]ピラジン−4(5H)−オン化合物およびMGLUR2受容体の負のアロステリック調節因子としてのそれらの使用
CN113508115A (zh) 吡啶并嘧啶酮和蝶啶酮化合物作为需要酶i(ire i α)的内切核糖核酸酶肌醇的抑制剂用于治疗癌症疾病
CN107667092A (zh) 作为fgfr4抑制剂的甲酰化n‑杂环衍生物
JP2025533831A (ja) Kras g12c変異タンパク質のテザー型複素環式阻害剤及びその使用
CN106336413A (zh) 作为jak抑制剂的化合物及其用途
JPWO2023064366A5 (enExample)
JP2025538452A (ja) 9型ホスホジエステラーゼの阻害による特定の神経精神障害の治療または予防におけるセロトニン作動性幻覚薬の効力の増強
KR20150036763A (ko) 축환 복소환 화합물